Literature DB >> 21467726

A novel mutation ApoE2 Kurashiki (R158P) in a patient with lipoprotein glomerulopathy.

Takehiko Tokura1, Seiji Itano, Shinya Kobayashi, Atsunori Kuwabara, Sohachi Fujimoto, Hideyuki Horike, Minoru Satoh, Norio Komai, Naruya Tomita, Akira Matsunaga, Takao Saito, Tamaki Sasaki, Naoki Kashihara.   

Abstract

Lipoprotein glomerulopathy (LPG) is a rare glomerulopathy caused by lipoprotein thrombi. In almost all cases of LPG, several apolipoprotein (apo) E mutations were reported. Here, we present a case of LPG caused by a novel mutation that we named ApoE2 Kurashiki, which substitutes arginine with proline at apoE codon 158. ApoE2 polymorphism is well known for its relationship to type III hyperlipoproteinemia, and the common apoE2 isoform is encoded by the R158C allele. ApoE2 Kurashiki substitutes at the same codon and cannot be distinguished from common apoE2 by stan-dard apoE genotyping or phenotyping.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21467726     DOI: 10.5551/jat.8102

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  10 in total

1.  Five-year follow-up of a case of lipoprotein glomerulopathy with APOE Kyoto mutation.

Authors:  Ryosuke Usui; Masaki Takahashi; Kosaku Nitta; Minako Koike
Journal:  CEN Case Rep       Date:  2016-03-04

Review 2.  An Updated Review and Meta Analysis of Lipoprotein Glomerulopathy.

Authors:  Meng-Shi Li; Yang Li; Yang Liu; Xu-Jie Zhou; Hong Zhang
Journal:  Front Med (Lausanne)       Date:  2022-05-06

Review 3.  Apolipoprotein E mutations: a comparison between lipoprotein glomerulopathy and type III hyperlipoproteinemia.

Authors:  Akira Matsunaga; Takao Saito
Journal:  Clin Exp Nephrol       Date:  2014-02-26       Impact factor: 2.801

Review 4.  A possible structural basis behind the pathogenic role of apolipoprotein E hereditary mutations associated with lipoprotein glomerulopathy.

Authors:  Efstratios Stratikos; Angeliki Chroni
Journal:  Clin Exp Nephrol       Date:  2013-10-23       Impact factor: 2.801

5.  Thermodynamic and structural destabilization of apoE3 by hereditary mutations associated with the development of lipoprotein glomerulopathy.

Authors:  Dimitra Georgiadou; Kostas Stamatakis; Eleni K Efthimiadou; George Kordas; Donald Gantz; Angeliki Chroni; Efstratios Stratikos
Journal:  J Lipid Res       Date:  2012-10-30       Impact factor: 5.922

6.  Lipoprotein glomerulopathy induced by ApoE Kyoto mutation in ApoE-deficient mice.

Authors:  Hongyan Wu; Jing Yang; Yun-Qiang Liu; Song Lei; Mei Yang; Zhi Yang; Yuan Yang; Zhangxue Hu
Journal:  J Transl Med       Date:  2021-03-04       Impact factor: 5.531

7.  A novel apolipoprotein E mutation, ApoE Ganzhou (Arg43Cys), in a Chinese son and his father with lipoprotein glomerulopathy: two case reports.

Authors:  Runxiu Wang; Chengbo Zhao; Wen Chen; Zhiping Liu; Fuhua Xie
Journal:  J Med Case Rep       Date:  2022-02-23

8.  Whole Exome Sequencing Reveals a Novel APOE Mutation in a Patient With Sporadic Early-Onset Alzheimer's Disease.

Authors:  Jaya Bagaria; Yeonsil Moon; Eva Bagyinszky; Kyu Hwan Shim; Seong Soo A An; SangYun Kim; Seol Heui Han
Journal:  Front Neurol       Date:  2022-06-10       Impact factor: 4.086

9.  The Novel Apolipoprotein E Mutation ApoE Chengdu (c.518T>C, p.L173P) in a Chinese Patient with Lipoprotein Glomerulopathy.

Authors:  Hongyan Wu; Yuan Yang; Zhangxue Hu
Journal:  J Atheroscler Thromb       Date:  2018-02-02       Impact factor: 4.928

10.  Lipoprotein glomerulopathy associated with the Osaka/Kurashiki APOE variant: two cases identified in Latin America.

Authors:  Joaquim Nelito da Silveira-Neto; Guilherme Jinson de Oliveira Ahn; Precil Diego Miranda de Menezes Neves; Vinicius Augusto Ferreira Baptista; Stanley de Almeida Araújo; David Campos Wanderley; Andréia Watanabe; Elieser Hitoshi Watanabe; Neide Missae Murai; Eny Maria Goloni Bertollo; Osvaldo Merege Vieira-Neto; Márcio Dantas; Sergio Ricardo de Antônio; Roberto Silva Costa; Maria Alice Sperto Ferreira Baptista; Miguel Moysés-Neto; Luiz Fernando Onuchic
Journal:  Diagn Pathol       Date:  2021-07-26       Impact factor: 2.644

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.